Back to Journals » Vascular Health and Risk Management » Volume 10

Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar

Authors Cho JR, Rollini F, Franchi F, Ferrante E, Angiolillo D

Received 14 January 2014

Accepted for publication 4 February 2014

Published 3 April 2014 Volume 2014:10 Pages 177—188

DOI https://doi.org/10.2147/VHRM.S36045

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3


Jung Rae Cho, Fabiana Rollini, Francesco Franchi, Elisabetta Ferrante, Dominick J Angiolillo

University of Florida College of Medicine – Jacksonville, Jacksonville, FL, USA

Abstract: Platelet activation with subsequent aggregation is a complex process leading to thrombus formation, which remains a key component for atherothrombotic manifestations, in particular myocardial infarction. Therefore, antiplatelet therapies are pivotal for the treatment of these patients. Current oral antiplatelet therapies used for secondary prevention of ischemic recurrences include aspirin and adenosine diphosphate P2Y12 platelet-receptor antagonists. However, despite these therapies, patients who have experienced a myocardial infarction remain at risk for ischemic recurrences. Therefore, more aggressive secondary prevention measures have been an area of research, including identifying additional targets modulating platelet-activation and -aggregation processes. Among these, thrombin-mediated platelet activation via protease-activated receptors (PARs) has been subject to extensive clinical investigation. Several PAR-1 receptor antagonists have been developed. However, vorapaxar is the only one that has completed large-scale clinical investigation. The present manuscript will provide an overview on the role of thrombin-mediated signaling, the impact of PAR-1 blockade with vorapaxar on ischemic and bleeding outcomes, and the potential role for vorapaxar in clinical practice.

Keywords: platelet aggregation, antiplatelet agent, protease-activated receptor 1, vorapaxar

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]